All In Biotech

NDA 019221 · Bausch

Vaseretic

Enalapril Maleate, Hydrochlorothiazide · Oral · Thiazide Diuretic

Last checked: Nov 19, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Oct 31, 1986

Approved uses

2

Original approval plus efficacy supplements

Registered trials

156

43 Phase 3, 13 recruiting

FAERS reports

912

787 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. • When pregnancy is detected, discontinue VASERETIC ® as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity

What it is approved for

From the label in effect Aug 31, 2020.

INDICATIONS AND USAGE VASERETIC is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using VASERETIC, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of VASERETIC, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema ).

Mechanism: Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 12, 1995 Supplement 15 · Efficacy
  • Oct 31, 1986 Original approval · Type 4 - New Combination
2 products under this application
  • VASERETIC · ENALAPRIL MALEATE 5MG; HYDROCHLOROTHIAZIDE 12.5MG · TABLET, ORAL · Prescription · TE AB
  • VASERETIC · ENALAPRIL MALEATE 10MG; HYDROCHLOROTHIAZIDE 25MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.

All 156 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction58
  • diarrhoea54
  • nausea48
  • fall45
  • renal failure acute44
  • dizziness38
  • vomiting36
  • hypotension35
  • hyponatraemia34
  • renal failure34
  • dyspnoea32
  • drug ineffective31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200473
200579
200667
200742
200873
200972
201085
2011120
201290
201311
201422
201517
201619
201713
201836
201924
202031
202113
20225
20239
20244
20256
20261

Recalls

1 FDA enforcement reports for this application.

  • May 21, 2014 · Class III · Terminated

    Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package outset

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vaseretic (Enalapril/Hydrochlorothiazide)

2024 spending

$76K

Beneficiaries

47

111 claims

Per beneficiary

$1,628

$11.08 per unit

View as table
YearSpending
2020$234,107
2021$177,429
2022$139,691
2023$80,586
2024$76,499

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,932 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.